Alison Stopeck ABRCC-2

    Clinical Researchers Showcase Series - August 2015

    Translational Medicine Research:

 View from the Trenches Newsletter

box_top.gif

Brought to you by:

Criterium Logo Alt Tag Line w Globe Banner 2

Translational science is motivated by the need to provide effective treatments to the right patients at the right doses for a specific disease indication). The term is used mostly in the health sciences and refers to real-time translation of bench science, conducted

only in a lab, to bedside clinical practice or dissemination

to population-based community interventions.

-  Source: NIH -- Read more


from the
Academic Breast Cancer Consortium

ABRCC Researcher Spotlight:

MEET Dr. Alison Stopeck, M.D.
Stony Brook University, Stony Brook, NY

ABRCC Investigator


Dr. Alison Stopeck, Chief, Division of Hematology/Oncology, Professor, Department of Internal Medicine, Associate Director for Translational Research, Stony Brook Cancer Center.

 

She obtained her MD degree from Columbia University College of Physicians and Surgeons, NY.  She did her residency in Internal Medicine, at Columbia Presbyterian Medical Center, NY and a Fellowship in Hematology/Oncology at Cornell University Medical College, NY.   She is board certified from the American Board of Internal Medicine, subspecialties in Hematology and Medical Oncology.

As for Dr. Stopeck’s research interests, she is currently involved in clinical trials targeting patients with breast cancer who are receiving chemotherapy.  Dr. Stopeck is the principal or collaborating investigator on multiple clinical trials involving novel agents, prognostic markers and predictors of response in breast cancer patients, as well as supportive care and survivorship issues in breast cancer.  Dr. Stopeck has numerous publications in medical journals and textbooks, including the New England Journal of Medicine and the Journal of Clinical Oncology.  She acts as an Associate Editor for the American Journal of Medicine and is an ad hoc reviewer for several journals. She has been a funded investigator from the NCI for over a decade.

Her honors and awards include:
Who's Who in America-Professional Edition;
2014 - Best Doctors in America, Woodward/White, Inc

 

About Stony Brook University Medicine
Long Island’s premier academic medical center, Stony Brook Medicine represents Stony Brook University’s entire medical enterprise and integrates Stony Brook’s health-related initiatives: education, research and patient care. It encompasses Stony Brook University Hospital, the five Health Sciences schools — Dental Medicine, Health Technology and Management, Medicine, Nursing and Social Welfare — as well as the major centers and institutes, programs and more than 50 community-based healthcare settings throughout Suffolk County.

Learn more at:

http://www.stonybrookmedicine.edu/patientcare/aboutus

box_bottom.gif

About the CONSORTIA MODEL 
for Translational Research

The important conceptual difference between the two predominant research group approaches used today (a Clinical Trials Group vs. Consortia) is seen in this consortia model.  With its highly experienced clinical scientists, ABRCC becomes involved on an intellectual advisory level with every step of clinical investigation in a breast cancer study. Classical clinical trials groups "just run the study" with the main substantive role being patient accrual.

 

To read more on ABRCC and the details of why the consortia model creates fast results, please visit our website.


The Oncology Consortia of Criterium

The Oncology Consortia of Criterium Global CRO are a collaboration of outstanding Cancer Research Consortia that deliver innovative research and unparalleled expertise:

  • AGICC:  Academic GI Cancer Consortium
  • AMyC:  Academic Myeloma Consortium
  • ATOMIC:  Academic Thoracic Oncology Medical Investigators Consortium
  • ABRCC:  Academic Breast Cancer Consortium

ABRCC Cube FULL Logo 2

Read more about Criterium Inc Global CRO

and The Oncology Consortia of Criterium on our website